Immunology and Microbiology
Severe Acute Respiratory Syndrome Coronavirus 2
100%
Influenza
86%
Immunology
85%
B Cell
56%
Influenza Virus
53%
Monoclonal Antibody
41%
Antibody Response
41%
Spike
40%
Viral Disease
39%
Memory B Cell
39%
Germinal Center
37%
Epitope
34%
Hemagglutinin
30%
Influenza A Virus (H1N1)
27%
Neutralizing Antibody
27%
COVID-19
22%
Influenzavirus A
20%
Influenza Vaccine
19%
Neutralization
18%
Immunity
18%
Influenza A Virus (H5N1)
17%
Plasmablast
16%
T Cell
14%
Blood Plasma
14%
Lymph Node
14%
Receptor Binding
13%
Omicron Coronavirus Variant
13%
Immune Response
12%
Immunogenicity
10%
Cytotoxic T-Cell
10%
Human Monoclonal Antibody
10%
Humoral Immunity
10%
Titer
9%
Glycoprotein
9%
Immunoglobulin Producing Cell
9%
Inflammatory Disorder
9%
Polyclonal Antibody
8%
Naive B Cell
8%
Intravenous Immunoglobulin
8%
Antigen Specificity
8%
Immunosuppression
8%
Viral Load
8%
Antibody Blood Level
8%
Maturation
8%
Vaccination
8%
Cytokine
8%
Ebola Virus
8%
Human Immunodeficiency Virus
7%
Somatic Hypermutation
7%
Mustela Putorius Furo
7%
Keyphrases
COVID-19
87%
Vaccination
56%
Influenza Virus
49%
Monoclonal Antibody
49%
Influenza
42%
Memory B Cells
41%
Antibody Response
38%
Neuraminidase
35%
B Cell Response
34%
Virus
30%
B Cells
29%
Vaccine Response
25%
Germinal Center
24%
Hemagglutinin
23%
Influenza-like Illness
22%
Influenza Vaccine
22%
Neutralizing Antibodies
21%
Plasmablast
21%
Broadly Protective
21%
Epitope
20%
Germinal Center Reaction
20%
Germinal Center B Cells
20%
MRNA Vaccine
20%
H5N1
17%
Influenza Vaccination
17%
Severe Acute Respiratory Syndrome Coronavirus 2 Infection
17%
Human Antibody
14%
Pre-existing Immunity
14%
Conserved Epitopes
14%
Immunization
14%
Antibody Targeting
14%
Virus Infection
13%
Immune Response
13%
Active Sites
11%
SARS-CoV-2 Variants
11%
Receptor-binding Domain
11%
Somatic Hypermutation
11%
Protective Antibodies
11%
SARS-CoV-2 Infection
11%
Bronchoalveolar Lavage
11%
Neutralizing Activity
10%
Naïve B Cells
10%
Spike Protein
10%
T Cells
10%
Antigen-specific
9%
Chronic Inflammatory Diseases
9%
Vaccine Development
9%
H1N1
9%
Bone Marrow Plasma Cells
9%
Lymph Node
9%